Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $12.26 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aptinyx Inc had its IPO on 2018-06-21 under the ticker symbol APTX.
The company operates in the Healthcare sector and Biotechnology industry. Aptinyx Inc has a staff strength of 40 employees.
Shares of Aptinyx Inc opened at $0.15 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $0.14 - $0.18, and closed at $0.18.
This is a +27.43% increase from the previous day's closing price.
A total volume of 15,834,167 shares were traded at the close of the day’s session.
In the last one week, shares of Aptinyx Inc have increased by +27.43%.
Aptinyx Inc's Key Ratios
Aptinyx Inc has a market cap of $12.26 million, indicating a price to book ratio of 0.3271 and a price to sales ratio of 45.3289.
In the last 12-months Aptinyx Inc’s revenue was $0 with a gross profit of $-54444000 and an EBITDA of $-70156000. The EBITDA ratio measures Aptinyx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aptinyx Inc’s operating margin was 0% while its return on assets stood at -42.08% with a return of equity of -90.04%.
In Q3, Aptinyx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 22.2%.
Aptinyx Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aptinyx Inc’s profitability.
Aptinyx Inc stock is trading at a EV to sales ratio of 73.9345 and a EV to EBITDA ratio of 0.3708. Its price to sales ratio in the trailing 12-months stood at 45.3289.
Aptinyx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $76.21 million
- Total Liabilities
- $2.69 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aptinyx Inc ended 2023 with $76.21 million in total assets and $0 in total liabilities. Its intangible assets were valued at $76.21 million while shareholder equity stood at $48.79 million.
Aptinyx Inc ended 2023 with $0 in deferred long-term liabilities, $2.69 million in other current liabilities, 677000.00 in common stock, $-340684000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $66.58 million and cash and short-term investments were $66.58 million. The company’s total short-term debt was $0 while long-term debt stood at $24.71 million.
Aptinyx Inc’s total current assets stands at $73.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $474000.00 and inventory worth $0.
In 2023, Aptinyx Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aptinyx Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aptinyx Inc stock is currently trading at $0.18 per share. It touched a 52-week high of $3.17 and a 52-week low of $3.17. Analysts tracking the stock have a 12-month average target price of $2.
Its 50-day moving average was $0.39 and 200-day moving average was $0.4 The short ratio stood at 0.38 indicating a short percent outstanding of 0%.
Around 1327.7% of the company’s stock are held by insiders while 4795.6% are held by institutions.
Frequently Asked Questions About Aptinyx Inc
Similar Industry Stocks (Biotechnology)
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson’s disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.